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U.K. Prospective Diabetes Study XV: Relationship of renin-angiotensin
system gene polymorphisms with microalbuminuria in NIDDM. We
performed a case-control study to determine whether molecular variants
of genes of the renin-angiotensin system were associated with the presence
of albuminuria in non-insulin dependent diabetes mellitus (NIDDM). A
total of 180 diabetic patients with persistent microalbuminuria [median
urinary albumin (interquartile range) of 74 (54 to 126 mg/liter)] were
matched with two control groups of diabetic patients without microalbu-
minuria [median urinary albumin 7 (5 to 10) mg/liter] for variables known
to be associated with raised urinary albumin concentration including
hemoglobin Ale and triglyceride. One control group was also matched for
blood pressure and the other group was not, to allow assessment of
interactions with hypertension. Association with the lID polymorphism of
the ACE gene and M235T variant of the angiotensinogen gene (AGT)
with microalbuminuria and retinopathy was examined. There were no
significant differences in genotype frequency between cases and controls
for ACE or AGT irrespective of blood pressure matching. However,
among subjects with microalbuminuria, those with the ACE DD genotype
had a significantly greater urinary albumin excretion than individuals with
a non-DD genotype [median 88 (68 to 170) mg/liter vs. 67 (53 to 113)
mg/liter, P < 0.001]. More subjects with the DD than non-DD genotype
had persistent albuminuria > 100 mg/liter, twice the upper normal range
(60% vs. 38%, P = 0.006). When increased albumin excretion occurs, the
presence of the ACE DD genotype appears to be associated with higher
urinary albumin levels. No association with retinopathy was observed.
In non-insulin dependent diabetes mellitus (NIDDM), mi-
croalbuminuria is a major determinant of premature death from
cardiovascular disease as well as identifying patients at risk of
developing overt proteinuria and diabetic nephropathy [1, 2]. It
has been suggested that the interaction of glycemic control with
putative genetic factors determines a predisposition to microvas-
cular complications. Family studies to determine whether
NIDDM and diabetic nephropathy co-segregate in Caucasian
populations have not been performed, partly because the late
onset and early mortality from cardiovascular disease makes
identification of two generation Caucasian families difficult. Pima
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Indians however, have a high prevalence and early age of onset of
NIDDM and studies in two generation families have revealed
familial clustering of nephropathy [3]. In addition, the contrasting
incidence of end-stage renal failure in NIDDM patients from
different ethnic groups within the UK provides indirect evidence
for the role of genetic determinants [4].
Components of the renin-angiotensin system (RAS) are impor-
tant candidate genes to examine for an association with mi-
croalbuminuria and diabetic nephropathy. Within the kidney,
angiotensin II increases intraglomerular pressure and glomerular
filtration rate [5], factors thought to be important in the patho-
genesis of diabetic glomeruloscierosis. In addition, the use of
ACE inhibitors has been shown to be protective, retarding the
rate of progression of diabetic nephropathy [6, 7]. An insertion!
deletion (l/D) polymorphism of the ACE gene arising from the
presence or absence of a 287 base pair Alu repeat element in
intron 16 has been associated with serum ACE levels [8, 9] and
risk of myocardial infarction in a non-diabetic population [10]. We
have recently confirmed this observation in a large NIDDM
population [11]. An association has been reported between the
I/D polymorphism of the ACE gene and diabetic nephropathy in
IDDM patients [12, 13], although other investigators have not
confirmed this finding [14]. In contrast, the angiotensinogen gene
has been genetically linked to hypertension [15] and a molecular
variant M235T arising from the substitution of C for T at
nucleotide 704 has been associated with angiotensinogen levels,
essential hypertension and pre-eclampsia [15, 16].
The U.K. Prospective Diabetes Study (UKPDS) was started in
1977 as a multi-center, prospective randomized intervention trial
of 5,102 newly diagnosed NIDDM patients [17]. The primary aims
are to determine whether improved blood glucose control will
prevent complications and reduce morbidity and mortality. Using
this population we have performed a case-control study to deter-
mine whether associations exist between polymorphisms of the
ACE and angiotensinogen genes and microalbuminuria in
NIDDM. We also assessed the relationship of these polymor-
phisms with retinopathy.
Methods
Urine albumin was measured annually by immuno-turbidimetry
in 4,860 Type 2 diabetic patients in the UKPDS [17, 18]. Urine
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Table 1. Characteristics of Type 2 diabetic patients with albuminuria and with normal albumin excretion matched for gender, age and variables
associated with increased albumin excretion, including HbAlc and triglyceride
Matched excluding blood pressure Matched including blood pressure
Increased Normal Increased Normal
albumin albumin albumin albumin
excretion excretion excretion excretion
N 158 158 144 144
Gender—male N (%) 105 (67) 105 (67) 98 (68) 98 (68)
Age (years)
Body mass index (kg m2)
53 (8)
29.4 (5.5)
53 (8)
28.6 (4.1)
53 (8)
29.5 (5.6)
53 (8)
29.0 (4.8)
HbA1 % 7.2 (1.6) 7.0 (1.4) 7.1 (1.6) 6.9 (1.3)
LDL (mmol/l) 3.5 (3.0 to 4.3) 3.6 (2.9 to 4.3) 3.4 (3.0 to 4.3) 3.5 (3.0 to 4.2)
Triglyceride (mmol/l) 1.8 (1.2 to 2.9) 1.8 (1.4 to 2.6) 1.8 (1.3 to 2.9) 1.7 (1.3 to 2.5)
HDL (mmol/l) 1.02 (0.89 to 1.19) 0.99 (0.86 to 1.15) 1.04 (0.89 to 1.19) 0.99 (0.86 to 1.12)
Systolic BP (mm Hg) 138 (125 to 151) 134 (120 to 148)" 135 (125 to 150) 138 (125 to 150)
Diastolic BP (mm Hg) 85 (76 to 92) 82 (76 to 90) 85 (76 to 91) 83 78 to 91)
Hypertension/normotension N (%) 91(58) 68 (43)" 78 (54) 77 (53)
Smoking status N (%) 39/57/62 49/58/51 34/53/57 41/63/40
(non-smoker/ex-smoker/current) (25/36/39) (3 1/37/32) (24/37/40) (29/44/28)
Retinopathy at diagnosis N(%) 90/14/13 104/17/10 84/10/11 87/16/4
(none/minimal/mild) (77/12/11) (79/13/8) (80/10/11) (81/15/4)
Urine albumin mg/liter 75 (54 to 130) 7 (5 to 9) 74(55 to 122) 8 (5 to 10)
In the left panel subjects are matched irrespective of blood pressure and in the right panel including blood pressure. Median (interquartile range)
or mean (SD) when normally distributed.
ap < 0.05
5p <0.01
"P < 0.001
albumin concentration was corrected for dilution of the urine by
regression on the urine creatinine concentration to 8 mg/liter in
women and 11 mg/liter in men, and expressed as urine albumin
concentration in mg/liter [19]. The median of three annual values
taken at one year, two years and three years after diagnosis of
diabetes for all subjects was 11 (7 to 22 mg/liter interquartile
range). In each year patients were ranked with a computer
program by median urine albumin values. Cases with raised urine
albumin excretion were defined when all three annual measure-
ments were in the top tertile and two of the three annual
measurements were in the top sextile. One hundred and eighty
Caucasian patients were thus identified with a median urinary
albumin concentration over the three years of 74 (54 to 126
mg/liter). Caucasian control patients irs whom none of the three
annual urinary albumin measurements were in the top tertile of
the distribution and whose median urinary albumin concentration
over the three years was 7 (5 to 10) mg/liter were identified. The
urine albumin concentration in the control group was similar to
that in a non-diabetic age-matched population [mean (SD interval)
7 (3 to 17) mg/liter] in which 50 mg/liter was the 96th percentile
[20]. For each case a matched control subject was sought accord-
ing to gender, age at diagnosis (within 5 years) and for variables
known to be associated with raised urinary albumin concentration
including hemoglobin Aic (within 2.0%) and triglyceride (in the
same quartile). As raised blood pressure is associated with
albuminuria and common genes may predispose to both hyper-
tension and diabetic nephropathy, control groups matched and
unmatched for blood pressure were chosen to assess a possible
interaction with hypertension. In the unmatched for hypertension
control group, 158 cases were matched with controls within the
above criteria. For the hypertension matched group, each case
and control was categorized as normotensive or hypertensive,
defined as receiving antihypertensive medication or having a
mean systolic and diastolic blood pressure greater than 160 mm
Hg and 90 mm Hg at two and nine months after diagnosis,
respectively. Within that category a control subject that matched
all the above criteria was also matched for systolic (within 15 mm
Hg) and diastolic (within 10 mm Hg) blood pressure. In this way,
144 pairs of cases were matched for hypertension/normotension
categorization and blood pressure levels (Table 1).
DNA extraction and polymerase chain reaction
DNA was extracted from leukocytes according to the manufac-
turer's recommendation using the Nucleon II DNA extraction kit
(Scotlab, Strathclyde, Scotland, UK).
The insertion/deletion polymorphism in intron 16 of the ACE
gene was detected using the polymerase chain reaction and
flanking oligonucleotide primer combinations as described previ-
ously [21]. Each 25 .d reaction mixture contained 100 ng of
genomic DNA, reaction buffer (50 mrvi KCI, 10 mrt Tris-HC1 pH
8.3 25°C, 1.5 m'vi MgCl2, 0.001% gelatin), I I.LM of each primer,
200 j.LM of each dNTP and 1 unit of Taq DNA polymerase
(Advanced Biotechnologies). The DNA was amplified for 30
cycles with denaturation at 94°C for one minute, annealing at 60°C
for one minute and extension at 72°C for one minute using a
Perkin-Elmer/Cetus DNA thermal cycler. Preferential amplifica-
tion of the smaller 190 bp "deletion" allele (D) in ID heterozy-
gotes has led to their mistyping as DD homozygotes [22]. To
exclude this possibility all DD homozygotes were retyped using an
I specific sense primer as previously described [22]. Similar
conditions to those described above were employed except that
5% DMSO was included in all of the reactions and the reaction
buffer contained 1.0 mM MgCl2. The thermal cycling conditions
used were 94°C for one minute, 65°C for one minute and 72°C for
one minute repeated for 10 cycles followed by 90°C for 30
seconds, 65°C for one minute and 72°C for 30 seconds repeated
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Table 2. Relationship of ACE gene genotypes with albuminuria status
Matched excluding Matched including
All subjects blood pressure blood pressure
Increased Normal Increased Normal Increased Normal
albumin albumin albumin albumin albumin albumin
Genotype excretion excretion excretion excretion excretion excretion
DD 47 (28.8) 70 (26.2) 47 (29.8) 36 (22.8) 41 (28.5) 42 (29.2)
ID 85 (51.2) 148 (55.4) 82 (51.9) 87 (55.1) 74 (51.4) 79 (54.8)
II 31 (19.0) 49 (18.4) 29 (18.3) 35 (22.1) 29 (20.1) 23 (16.0)
N 163 267 158 158 144 144
x 0.48 on 2 d.f. 2.168 on 2 d.f 0.868 on 2 d.f.
P 0.787 0.338 0.648
The left panel is for all subjects, the middle panel for those matched
excluding hypertension (see Table 1 caption) and the right panel matching
for blood pressure. showed no significant relationships either with DD,
ID and II genotypes or with DD and non-DD genotypes.
for 30 cycles. Amplification products were separated by agarose
gel electrophoresis and visualized under ultraviolet light after
ethidium bromide staining.
The hypertension-associated T235 allele of the human angio-
tensinogen gene was detected by PCR amplification of genomic
DNA followed by restriction endonuclease digestion by Tthlll I
[231. The T-C transition at nucleotide 704 in exon 2 produces a
'half site' for Tthlll I digestion and introduction of the corre-
sponding half site is achieved using a PCR primer with 2
mismatches. The amplification yields a product of 165 base
(M235) pairs which in the presence of C at position 704 results in
cleavage by Tthlll I to generate a fragment of 141 bp (T235).
The allele frequencies in this population for the insertion!
deletion polymorphism of the ACE gene and for the M235T
polymorphism were in Hardy-Weinberg equilibrium and were
similar to allele frequencies obtained in other West European
Caucasian populations [10, 24].
Statistics
Statistical analysis was performed using the SAS package (SAS
Institute mc, Cary, NC, USA) on a VAX computer. Paired
samples of normally distributed continuous variables were com-
pared by paired t-test and non-parametric data by Wilcoxon
signed rank test. Categorical data were compared using chi-square
test and McNemar's test statistic.
Results
Table 1 shows the characteristics of cases and controls accord-
ing to blood pressure matching. The exclusion of cases reflects an
inability to identify control subjects within the strict criteria
defined for matching. When matched for age, gender, hemoglobin
Ale and triglyceride but not blood pressure, hypertension was
more common in those subjects with increased albumin excretion
(58% vs. 43%, P < 0.001). In spite of the greater prevalence of
treated hypertension (25% vs. 21%), subjects with microalbumin-
uria had a higher median systolic blood pressure (138 vs. 134 mm
Hg, P < 0.05). The groups were well matched for other variables.
Table 2 shows the relationship of ACE gene l/D genotypes in
cases and controls for all subjects and according to blood pressure
matching status. When unmatched for blood pressure, there was a
trend for more DD genotypes in cases with increased albumin
excretion compared to controls (47 vs. 36, respectively), although
this was not significant. When matched for blood pressure, the
number of cases and controls with the DD genotype were 41 and
42, respectively. Similarly, the II genotype was equally repre-
sented in both cases and controls irrespective of blood pressure
matching.
Table 3 shows the characteristics of all patients according to the
presence or absence of microalbuminuria and ACE genotype
(DD or non-DD). Among subjects with microalbuminuria, those
with the ACE DD genotype had a significantly greater urinary
albumin excretion than individuals with a non-DD genotype
[median (interquartile range) 88 (68 to 170) mg/liter vs. 67 (53 to
113) mg/liter, P < 0.001). Table 3 shows that the patients with DD
and non-DD ACE genotypes had no significant differences for any
of the known confounding variables including blood pressure. The
proportion on therapy for hypertension was also similar, 12% and
14%, respectively. The data suggest that when increased albumin
excretion occurs, the presence of the ACE DD genotype is
associated with higher urinary albumin levels. Indeed, the propor-
tion of patients with a urinary albumin >100 mg/liter (twice the
upper normal range) in patients with DD compared with non-DD
genotype was 1.63 times greater [29/47 (62%) vs. 44/116 (38%),
respectively, P = 0.006]. There was no association between ACE
genotype and increased urinary albumin excretion when the data
were analyzed according to blood pressure status (Table 4).
Diabetic retinopathy was similarly prevalent in subjects with
and without increased urine albumin excretion (Table 1) and
showed no association with ACE genotype (Table 3).
There was no association between the angiotensinogen gene
M235T polymorphism and urinary albumin (Table 5). Furthermore,
there was no interaction between angiotensinogen and ACE geno-
types and increased urinary albumin excretion (Table 6).
Discussion
In this matched case-control study of NIDDM subjects, there
was no association between either an insertion/deletion polymor-
phism of the ACE gene, or the M235T polymorphism of the
angiotensinogen gene with categorisation of patients into groups
with increased or normal urinary albumin excretion. Although not
related to the case-control design, among subjects with a raised
urinary albumin excretion, individuals with the DD ACE genotype
had significantly more severe albuminuria than those patients with
a non-DD genotype. This observation suggests the hypothesis that
the presence of the DD genotype may be an additional factor
increasing albuminuria in subjects already with microalbuminuria
for other reasons. As such, it may play a role in the progression of
microalbuminuria to overt proteinuria and subsequent diabetic
nephropathy. This would be in keeping with the known physio-
logical effect of angiotensin II in the kidney as well as the
beneficial effects of pharmacological treatment with ACE inhibi-
tion in slowing the progression of diabetic nephropathy. It may
also explain in part the association between microalbuminuria and
cardiovascular disease in NIDDM patients. Recently we have
shown that the DD genotype is a significant independent risk
factor for myocardial infarction in NIDDM patients [11].
Although hypertension was shown to be associated with in-
creased albumin excretion, there was no interaction between the
DD genotype and blood pressure in increasing urinary albumin
excretion.
The role of the ACE DD genotype in nephropathy associated
with IDDM is controversial. A significant association between the
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Table 3. Characteristics of Type 2 diabetic subjects according to albuminuria status and presence or absence of DD genotype of ACE gene lID
polymorphism
Genotype
Increased urinary
albumin excretion
Normal urinary
albumin excretion
DD Non-DD DD Non-DD
N
Age years
Gender, male, N %
BMI kg m2
HbA1, %
LDL cholesterol mmol/liter
Triglyceride mmol/liter
HDL cholesterol mmol/liter
Systolic BP mm Hg
Diastolic BP mm Hg
Hypertensive, N %
Retinopathy
None/minimal/mild, N %
Urine albumin mg/liter
47 116
54 (9) 52 (9)
34 (72) 75 (65)
29.3 (4.9) 29.6 (5.8)
7.2 (1.6) 6.9 (1.6)
3.3 (2.8 to 4.7) 3.6 (3.1 to 4.2)
1.7 (1.3 to 2.2) 1.8 (1.2 to 2.9)
1.10 (0.91 to 1.23) 1.02 (0.87 to 1.17)
136 (126 to 155) 135 (124 to 150)
85 (77 to 92) 85 (76 to 90)
29 (61) 65 (56)
33/2/3 62/12/10
(87/5/8) (74/14/1 2)
88 (68 to 170) 67 (53 to 113)
70 197
52 (8) 53 (8)
42 (60) 138 (70)
29.4 (5.1) 28.8 (4.7)
7.0 (1.4) 6.9 (1.3)
3.5 (3.1 to 4.1) 3.5 (3.0 to 4.2)
1.7 (1.3 to 2.3) 1.7 (1.4 to 2.5)
0.92 (0.85 to 1.06) 1.01 (0.87 to 1.15)
134 (120 to 150) 139 (125 to 150)
85 (77 to 90) 83 (78 to 91)
33 (47) 96 (49)
43/6/5 128/21/8
(80/11/9) (82/13/5)
7 (6 to 11) 8 (5 to 10)
a P < 0.01 Median (interquartile range) or mean (SD) when normally distributed
Table 4. Interaction between DD genotype of ACE gene and
hypertension status assessed by median urine albumin concentrationsa
Median albumin excretion mg/liter,
and number of subjects (N)
Increased urine Normal urine
albumin albumin
DD Non-DD DD Non-DD
Normotensive 100 (18) 82(51) 7(37) 7(101)
Hypertensive 118 (29) 84 (65) 9(33) 8 (96)
a Geometric mean over 1, 2 and 3 years
Table 5. Lack of association between angiotensinogen gene genotypes
and albumin excretion in matched case-control study
Patients with increased albumin
excretion
Matched excluding Matched including
blood pressure blood pressure
Non-IT iT N Non-iT TT N
Patients with Non-iT 113 22 135 99 21 120
normal albumin iT 15 5 20 16 3 19
excretion N 128 27 155 115 24 139
McNemar's test NS NS
Data are presented according to blood pressure matching status. Each
cell shows the number of matched patients in the 2 groups of contrasting
urinary albumin excretion with the genotypes given for each group and
according to matching or not for blood pressure. The pairs of matched
patients in which the M235T polymorphisms were discordant were similar
in both the subjects matched, except for blood pressure (22 vs. 15 for TT
in microalbuminuria and control groups, respectively) and in those
matched including blood pressure (21 vs. 16, respectively).
D allele and microalbuminuria or overt proteinuria in insulin-
dependent diabetic subjects has been reported [13]. Marre et al
have reported a significant under representation of the II geno-
type in IDDM patients with microalbuminuria/persistent protein-
uria compared with controls despite a similar prevalence of
retinopathy [12]. They suggest that the presence of the II geno-
Table 6. Lack of interaction between ACE DD genotype and AGT
polymorphisms assessed by median (interquartile range) urine
albumin concentrations
Subjects with increased urine albumin excretion
DD Non-DD
MM 98 (75 to 170) 75 (55 to 121)
N 21 39
MT 85 (56 to 151) 63 (49 to 94)
N 24 49
iT 339(68to611) 83(6410146)
N 2 25
type is protective against the onset of diabetic nephropathy. In a
recent study examining the relationship between the l/D polymor-
phism of the ACE gene and renal hemodynamic dysfunction in
IDDM, the II genotype was found to be associated with an
elevated GFR arguing, against a protective effect acting via
modification of glomerular hemodynamics [25]. In contrast,
Schmidt et al, although initially reporting an association between
the DD genotype and nephropathy, found no significant associa-
tion after studying a larger number of patients [14].
We found no association of the DD genotype with the presence
or severity of diabetic retinopathy in NIDDM. This confirms a
similar observation made in patients with IDDM [121.
The way in which the DD ACE genotype contributes to more
severe albuminuria in non-insulin dependent diabetic subjects
with raised urinary albumin excretion, remains to be determined.
Although the lID polymorphism of the ACE gene is associated
with serum ACE levels, family data suggest that this polymor-
phism is in linkage disequilibrium with another regulatory poly-
morphism which determines serum ACE levels [9]. Because the
extent of linkage disequilibrium at this locus is unknown, the
mechanism by which the DD genotype might be related to the
severity of albuminuria is unclear.
Reprint requests to Dr. C.R.K. Dudley, Richard Bright Renal Department,
Southmead Hospita4 Westbury-on- Ttyni, Bristol BSIO 5NB, England, United
Kingdom.
Dudley et al: Genetic determinants of microalbuminuria in NIDDM 1911
References
1. MOGENSEN CE: Microalbuminuria predicts clinical proteinuria and
early mortality in maturity-onset diabetes. NEnglJMed 310:356—360,
1984
2. MOGENSEN CE, DAMSGAARD EM, FROLAND A, NIELSEN S, DE FINE
OuvARlus N, SCHMITZ A: Microalbuminuria in non-insulin-depen-
dent diabetes. Clin Nephrol 38(Suppl 1):S28—S39, 1992
3. Prrirr DJ, SD MF, BENNETT PH, NELSON RG, KNOWLER WC:
Familial predisposition to renal disease in two generations of Pima
Indians with Type 2 (non-insulin-dependent) diabetes mellitus. Dia-
betologia 33:438—443, 1990
4. GRENFELL A, BEWICK M, PARSONS V, SNOWDEN 5, TAUBE D, WATKINS
PJ: Non-insulin-dependent diabetes and renal replacement therapy.
Diabet Med 5:172—176, 1987
5. BALLERMAN BJ, ZEIDEL ML, GUNNING ME, BRENNER BM: Vasoac-
tive peptides and the kidney, in The Kidney, edited by BRENNER BM,
RECTOR FC, Philadelphia, Saunders, 1991, pp 510—583
6. Rvin M, SAVIN H, JIJTRIN 1, KATZ B, LISHNER M: Long-term
stabilizing effect of angiotensin-converting enzyme inhibition on
plasma creatinine and on proteinuria in normotensive type II diabetic
patients. Ann intern Med 118:577—581, 1993
7. VIBERTI G, MOGENSEN CE, GROOP LC, PAULS iF: Effect of captopril
on progression to clinical proteinuria in patients with insulin-depen-
dent diabetes mellitus and miroalbuminuria. European Microalbu-
minuria Captopril Study Group. JAMA 271:275—279, 1994
8. RIGAT B, HUBERT C, ALHENC-GELAS F, CAMBIEN F, CORVOL P,
SOUBRIER F: An insertion/deletion polymorphism in the angiotensin
I-converting enzyme gene accounting for half the variance of serum
enzyme levels. J Clin invest 86:1343—1346, 1990
9. TIRET L, RIGAT B, VI5vIKIS S, BREDA C, CORVOL P, CAMBIEN F,
SOUBRIER F: Evidence from combined segregation and linkage anal-
ysis that a variant of the angiotensin 1-converting enzyme (ACE) gene
controls plasma ACE levels. Am J Hum Genet 5 1:197—205, 1992
10. CAMBIEN F, P0IRIER 0, LECERF L, EVANS A, CAMBOU J-P, ARVEILER
D, LUC G, BARD J-M, BARA L, RICARD S, TIRET L, AMOUYEL P,
ALHENC-GELAS F, SOUBRIER F: Deletion polymorphism in the gene
for angiotensin-converting enzyme is a potent risk factor for myocar-
dial infarction. Nature 359:641—44, 1992
11. KEAVNEY B, DUDLEY C, STRATrON I, HOLMAN R, MAT-IHEWS D,
RATCLIFFE P, TURNER R: U.K. Prospective Diabetes Study (UKPDS)
XIV: Association of ACE insertion/deletion polymorphism with myo-
cardial infarction in non-insulin dependent diabetes (NIDDM). Dia-
betologia 38:948—952, 1995
12. MARRE M, BERNADET P, GALLOIS Y, SAVAGNER F, GUYENE T-T,
HALLAB M, CAMBIEN F, PASSA F, ALHENC-GELAS F: Relationship
between angiotensin I converting enzyme gene polymorphism, plasma
levels, and diabetic complications. Diabetes 43:384—388, 1994
13. FOGARTY DG, HUGHES AE, NEVIN NC, DOHERTY CC, MAXWELL AP:
Functional genetic markers of the renin-angiotensin system and the
risk of diabetic nephropathy in insulin-dependent diabetes melitus.
(abstract) JAm Soc Nephrol 5:376, 1994
14. SCHMIDT S, SCHONE N, GIESSEL R, BERGIS K, RITZ E: Association of
the ACE gene polymorphism and diabetic nephropathy. (abstract) J
Am Soc Nephrol 5:383, 1994
15. JEUNEMAITRE X, SOUBRIER F, KOTELEVTSEV YV, LWrON RP, WIL-
LIAMS CS, CHARRU A, HUNT SC, HOPKINS PN, WILLIAMS RR,
LALOUEL J-M, CORVOL F: Molecular basis of human hypertension:
Role of angiotensinogen. Cell 71:169—180, 1992
16. WARD K, HATA A, JEUNEMAITRE X, HELIN C, NELSON L, NAMIKAWA
C, FARRINGTON PF, OGASAWARA M, SUZUMORI K, TOMODA S,
BERREBI 5, SASAKI M, CORVOL P, LIFTON RP, LALOUEL J-M: A
molecular variant of angiotensinogen associated with preeclampsia.
Nat Genet 4:59—61, 1993
17. UK PROSPECTIVE DIABETES STUDY GROUP: UK Prospective Diabetes
Study (UKPDS) VIII. Study design, progress and performance.
Diabetologia 34:877—890, 1991
18. KEARNEY EM, MOUNT JN, WATrS GF, SLAVIN BM, KIND PRN:
Simple immunoturbidimetric method for determining urinary albumin
at low concentrations using a Cobas-Bio centrifugal analyser. J Clin
Pathol 40:465—468, 1987
19. THOMPSON SG, BARLOW RD, WALD NJ, VAN VUNAKIS H: How should
urinary cotinine concentrations be adjusted for urinary creatinine
concentration? Clin Chim Acta 187:289—296, 1990
20. UK PROSPECTIVE DIABETES STUDY GROUP: UK Prospective Diabetes
Study (UKPDS) XI: Biochemical risk factors in Type 2 diabetic
patients at diagnosis compared with age-matched normal subjects.
Diabetic Med 11:534—544, 1994
21. RIGAT B, HUBERT C, CORVOL F, SOUBRIER F: PCR detection of the
insertion/deletion polymorphism of the human angiotensin converting
enzyme gene (DCP1) (dipeptidyl carboxypeptidase). Nuci Acid Res
20:1433, 1992
22. SHANMUGAM V, SELL KW, SAHA BK: Mistyping ACE heterozygotes.
PCR Meth AppI 3:120—121, 1993
23. RUSS AP, MAERZ W, RUZICKA V, STEIN U, GROSS W: Rapid detection
of the hypertension-associated Met235-Thr allele of the human
angiotensinogen gene. Hum Mol Genet 2:609—610, 1993
24. CAULFIELD M, LAVENDER P, FARRALL M, MUNROE P, LAWSON M,
TURNER P, CLARK AJL: Linkage of the angiotensinogen gene to
essential hypertension. N Engi I Med 330:1629—1633, 1994
25. PEI Y, SCHOLEY J, PHAI K, MILLER JA: Relationship between
angiotensin I converting enzyme (ACE) gene polymorphism and renal
hemodynamic dysfunction in insulin dependent diabetes mellitus.
(abstract) JAm Soc Nephrol 5:382, 1994
